Vu. I noticed on Mr Mains BO list that you were 80% certain of a BO at $45 by 6/1/19.
Currently PPS is $20 roughly .
Would you really vote as a shareholder to sell the Co for $45 by 6/1/19 ? You haven't got the FDA decision yet , no EU plan or partner , no revised tier levels for insurance coverage , no real info on how much V will be prescribed off label once R-IT indication approved.
Theres a lot left to be done IMHO before either AMRN or a potential buyer could agree on a reasonable value for a sale.
If we get priority review , scripts continue to ramp as per poster curcuits graphs , no problem with MO at Adcom ( assuming there's one ) and full R-IT indication on approval followed by better tier ratings on insurance plans and continued off labels scripts being written plus an EU partner / plan ....price should be higher then $45
If Vascepa is the next best thing since Statins ( Dr Bhatts view ) then the Co should be worth a lot more in 2020 once FDA approval , better tiers /co pays etc etc are in place .
AMRN just needs to execute successfully on their announced strategy throughout 2019 , to get a higher price in 2020
I think anyone expecting a BO in 2019 is overly optimistic ...thats my guess
Kiwi
News 
Market Data 
Discover 
AI
